Investor Relations
Q Chip’s proprietary platform technology, MicroPlant™ was developed from research conducted in microfluidics at the University of Cardiff. After 4 years of intensive R&D this exclusive technology enables the precise packaging of high value fragile biological products in precision polymer microspheres. Analogous to Tetra Pak®, but at a much smaller scale (0.08mm-2mm in diameter) the technology has wide application for the encapsulation of biological materials.
Opportunities and Commercial Validation
Recent market research estimates sales of sustained release drug formulations to reach $36.1 billion in 2009 and to increase to $45.8 billion by 2014.
The Q-Sphera product range, manufactured using the MicroPlant advanced drug delivery system, is ideally positioned to take immediate advantage of significant market opportunities for sustained formulations.
Q Chip’s two lead compounds in its biogeneric pipeline are Q-Leuprolide (a 3 month sustained release formulation) and Q-Octreotide (a 1 month sustained release formulation). Both are currently available for out-licensing. Estimates of the total market size for leuprolide are $2 billion (for prostate cancer indications) and $1.2 billion for octreotide (for acromegaly indications). The biogenerics market is expected to be worth $10 billion by 2010.
Q Chip is seeking collaborative partnerships with companies who require sustained release formulations for protein biotherapies that require sub-cutaneous injection.
IP
Q Chip has a strong patent portfolio related to microsphere production using its MicroPlant platform and biogeneric manufacturing system.
Investors
Q Chip’s primary investors are:
- Curzon Park Capital
- E-Synergy
- Forum of The Future
- Fusion Cardiff Ltd
- Finance Wales Investments Ltd
- Capital Cardiff Investment Fund